These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

510 related items for PubMed ID: 30315932

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin.
    Okamoto K, Okamoto I, Hatashita E, Kuwata K, Yamaguchi H, Kita A, Yamanaka K, Ono M, Nakagawa K.
    Mol Cancer Ther; 2012 Jan; 11(1):204-13. PubMed ID: 22075159
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer.
    Shimizu T, Nishio K, Sakai K, Okamoto I, Okamoto K, Takeda M, Morishita M, Nakagawa K.
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):211-219. PubMed ID: 32638093
    [Abstract] [Full Text] [Related]

  • 5. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.
    Li YY, Lam SK, Mak JC, Zheng CY, Ho JC.
    Lung Cancer; 2013 Sep; 81(3):354-361. PubMed ID: 23769318
    [Abstract] [Full Text] [Related]

  • 6. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
    Chen P, Huang HP, Wang Y, Jin J, Long WG, Chen K, Zhao XH, Chen CG, Li J.
    J Exp Clin Cancer Res; 2019 Jun 13; 38(1):254. PubMed ID: 31196210
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
    Lv T, Li Z, Xu L, Zhang Y, Chen H, Gao Y.
    Acta Biomater; 2018 Aug 13; 76():257-274. PubMed ID: 29960010
    [Abstract] [Full Text] [Related]

  • 9. Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy.
    Li YL, Hu X, Li QY, Wang F, Zhang B, Ding K, Tan BQ, Lin NM, Zhang C.
    Mol Med Rep; 2018 Oct 13; 18(4):3882-3890. PubMed ID: 30106133
    [Abstract] [Full Text] [Related]

  • 10. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA, Xiao B, Zhao H, Al-Zahrani KN, Hasim MS, Villeneuve J, Sekhon HS, Goss GD, Sabourin LA, Dimitroulakos J, Addison CL.
    PLoS One; 2016 Oct 13; 11(3):e0150567. PubMed ID: 26962872
    [Abstract] [Full Text] [Related]

  • 11. The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib.
    Zou Y, Ling YH, Sironi J, Schwartz EL, Perez-Soler R, Piperdi B.
    J Thorac Oncol; 2013 Jun 13; 8(6):693-702. PubMed ID: 23575415
    [Abstract] [Full Text] [Related]

  • 12. JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
    Zhang FQ, Yang WT, Duan SZ, Xia YC, Zhu RY, Chen YB.
    Oncotarget; 2015 Jun 10; 6(16):14329-43. PubMed ID: 25869210
    [Abstract] [Full Text] [Related]

  • 13. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
    Smith DL, Acquaviva J, Sequeira M, Jimenez JP, Zhang C, Sang J, Bates RC, Proia DA.
    Target Oncol; 2015 Jun 10; 10(2):235-45. PubMed ID: 25077897
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.
    Yu W, Lu W, Chen G, Cheng F, Su H, Chen Y, Liu M, Pang X.
    Br J Pharmacol; 2017 Oct 10; 174(20):3608-3622. PubMed ID: 28749535
    [Abstract] [Full Text] [Related]

  • 15. [Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
    Han R, Wang X, Zhong D, Zhao J, Chen Z, Sun L, Wang J, Zhang J.
    Zhongguo Fei Ai Za Zhi; 2012 Dec 10; 15(12):689-93. PubMed ID: 23249714
    [Abstract] [Full Text] [Related]

  • 16. Targeting Epidermal Growth Factor Receptor by MiRNA-145 Inhibits Cell Growth and Sensitizes NSCLC Cells to Erlotinib.
    Amri J, Molaee N, Baazm M, Karami H.
    Asian Pac J Cancer Prev; 2019 Sep 01; 20(9):2781-2787. PubMed ID: 31554377
    [Abstract] [Full Text] [Related]

  • 17. Autophagy inhibition facilitates erlotinib cytotoxicity in lung cancer cells through modulation of endoplasmic reticulum stress.
    Wang Z, Du T, Dong X, Li Z, Wu G, Zhang R.
    Int J Oncol; 2016 Jun 01; 48(6):2558-66. PubMed ID: 27035631
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of JAK1/2 can overcome EGFR-TKI resistance in human NSCLC.
    Kim DM, Kim MJ, Moon JH, Lee EY, Hong JK, Lee S, Koh DI, Ryu YS, Kim SM, Jung SA, Shin JS, Kim J, Park YS, Hong SW, Lee SH, Jung J, Park SS, Kim DY, Kim EH, Jeong HR, Gong JH, Kim J, Chan Kim S, Yu HN, Ki SY, Kim TW, Jin DH.
    Biochem Biophys Res Commun; 2020 Jun 18; 527(1):305-310. PubMed ID: 32446385
    [Abstract] [Full Text] [Related]

  • 19. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y, Singh R, Wang L, Nilsson M, Goonatilake R, Tong P, Li L, Giri U, Villalobos P, Mino B, Rodriguez-Canales J, Wistuba I, Wang J, Heymach JV, Johnson FM.
    Oncotarget; 2016 Jul 26; 7(30):47998-48010. PubMed ID: 27384992
    [Abstract] [Full Text] [Related]

  • 20. Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.
    Hwang KE, Kwon SJ, Kim YS, Park DS, Kim BR, Yoon KH, Jeong ET, Kim HR.
    Exp Cell Res; 2014 May 01; 323(2):288-96. PubMed ID: 24631288
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.